Related Experiment Video
Updated: Mar 22, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Polymatin A from Smallanthus macroscyphus leaves: A safe and promising antidiabetic compound
Carolina Serra-Barcellona1, Stella M Honoré1, Wilfredo M Cabrera1
1Biological Research Institute (INSIBIO), National Council of Scientific and Technical Research (CONICET) and National University of Tucumán, Chacabuco 461, (T4000INI), San Miguel de Tucumán, Argentina.
Abstract:
Smallanthus macroscyphus is an herb native to South America whose leaves are a source of antidiabetic compounds, although complete information about their safe use is not available yet. This study was developed to evaluate the toxicity profile of both 10% decoction and the sesquiterpene lactone polymatin A from S. macroscyphus leaves through in vitro cytotoxicity assays and in vivo subchronic oral toxicity. Cell viability of Hep-G2, COS1, CHO-K1 and Vero cell lines decreased in a concentration-dependent manner when cells were incubated with 0.4-200 μg ml(-1) of dry extract or 0.12-60 μg ml(-1) of polymatin A. In subchronic studies, decoction was orally administered to Wistar rats for 90 days at daily doses of 70, 140 and 280 mg kg(-1) of dry extract, whereas polymatin A was administered in the same way at doses of 7, 14 and 28 mg kg(-1) . No toxicity signs or deaths were observed. There were no changes in the behavior, body or organ weights, hematological, biochemical or urine parameters of the rats. No histopathological lesions were observed in the examined organs. The results indicate that the 10% decoction and polymatin A from S. macroscyphus leaves may be considered as non-toxic substances at a wide range of doses, including the effective hypoglycemic dose. Copyright © 2016 John Wiley & Sons, Ltd.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Sulfonylureas
